Cibus, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Moby summary of Cibus, Inc.'s Q1 2026 earnings call
Cibus Inc (CBUS) strengthens its market position with significant progress in commercialization and regulatory support, despite facing financial hurdles and product launch delays.
Cibus (NASDAQ:CBUS) reported first-quarter 2026 results and said it is advancing toward commercialization across its rice and sustainable ingredients programs, while also reducing expenses and extending its cash runway into late in the first quarter of 2027. Peter Beetham, Cibus’ co-founder, interi
Cibus (CBUS) delivered earnings and revenue surprises of +5.71% and +29.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Cibus (CBUS) reported narrower Q1 loss, beating estimates via cost cutting. Stock jumped 15% after-hours on progress toward 2027 rice launch and reduced cash burn.
Cibus, Inc. (CBUS) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDTCompany ParticipantsCarlo Broos - Chief Financial OfficerPeter Beetham - Co-Founder,...
Cibus (NASDAQ:CBUS) reported quarterly losses of $(0.33) per share which met the analyst consensus estimate. This is a 55.41 percent increase over losses of $(0.74) per share from the same period last year. The company
Bioceres Crop (BIOX) delivered earnings and revenue surprises of -220.00% and -29.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Cibus (CBUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Represents achievement of strategic milestone for Cibus’ anticipated first commercial offering in the South American marketSAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of high-value plant traits, today announced the transfer of gene-edited materials for herbicide tolerance in rice to its partner, Interoc. This transition facilitates the commencement by Interoc of testing and product
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report first quarter 2026 financial results on Thursday, May 14, 2026. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. First Quarter 2026 Results Conference Ca
SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the election of Thomas Urban to its Board of Directors. “We are pleased to welcome Tom to the Cibus Board of Directors,” said Mark Finn, Chairman of the Board of Cibus. “As the Company pursues its commercialization initiatives, translating its trait pipeline into revenue producing
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at the gap up and gap down stocks in today's session.
Wondering what's happening in Thursday's pre-market session? Find an overview in this article.
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the pricing of an underwritten public offering (the “Offering”) of 6,976,744 shares of its Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”) at a purchase price of $2.15 per share of Class A Common Stock. The Company has also granted the underwriter a 30-da
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 11.43M | $22.62M | 0.00% | Added+56.1% | 2026-03-31 |
| StateStreet | passive | 157.2K | $311.23K | 0.00% | Added+108.0% | 2026-03-31 |
| RenTech | quant | 98.9K | $195.82K | 0.00% | Added+42.5% | 2026-03-31 |
| TwoSigma | quant | 86.2K | $170.69K | 0.00% | Added+97.4% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.19 | — | — |
| 2026-05-14 | -0.12 | -0.33 | -175.00% |
| 2026-03-17 | -0.15 | -0.42 | -178.07% |
| 2025-11-13 | -0.18 | -0.44 | -144.44% |
| 2025-08-14 | -0.33 | -0.61 | -84.85% |
| 2025-05-08 | -0.36 | -0.74 | -105.53% |
| 2025-03-20 | -0.76 | -0.87 | -14.47% |
| 2024-11-07 | -0.89 | 0.06 | +106.97% |
| 2024-08-08 | -0.82 | -1.14 | -39.02% |
| 2024-05-09 | -1.01 | -1.12 | -10.89% |
| 2024-03-21 | -2.05 | 2.92 | +242.40% |
| 2023-11-09 | -1.16 | -1.59 | -37.07% |
| 2023-08-10 | -1.00 | -3.05 | -205.00% |
| 2023-03-02 | -5.50 | -3.00 | +45.45% |
| 2022-11-03 | -7.50 | -6.50 | +13.33% |
| 2022-08-04 | -7.25 | -7.00 | +3.45% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CBUS | -0.69% | -59.21% | -17.24% | -55.42% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.66% | -54.57% | -13.80% | -68.11% |